Elicio Therapeutics, Inc ELTX 深 滬
等待開盤 03-26 09:30:00 美东时间
10.96
+0.410
+3.89%
華盛通- 最 高11.2999
- 今 開10.78
- 成交量 9.43万股
- 最 低 10.29
- 昨 收 10.55
- 總市值 1.92亿
- 52周最高 14.93
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 4.60
- 委 比 51.30%
- 總股本 1748.95万
- 歷史最高 263.00
- 量 比 0.72
- 振 幅 9.57%
- 歷史最低 2.96
- 每 手 1
- 風險率 2.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Elicio Therapeutics Launches $100M At-The-Market Offering Program, Replaces Prior $40M Sales Agreement
Entry into a Material Definitive Agreement.On March 16, 2026, Elicio Therapeutics, Inc. (the "Company") entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc.,
03-16 21:29
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Elicio Therapeutics Q4 EPS $(0.45) Beats $(0.47) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.47) by 3.23 percent. This is a 55.88 percent increase over losses of $(1.02) per share
03-13 04:20
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Rodman & Renshaw Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $17
Rodman & Renshaw analyst Michael King initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $17.
03-10 18:17
Elicio Therapeutics Files Preliminary Prospectus To Issue Up To $400M In Securities
-SEC Filing
02-28 05:32
Elicio Therapeutics Announces That Analysis Of Subset Of Patients In Ongoing Phase 2 AMPLIFY-7P Trial Shows That Majority Of Evaluated Patients Treated With ELI-002 7P Induced Antigen Spreading Targeting Non-mKRAS Neoantigens That Are Not Present In ELI-002 7P Targeted Immunotherapy
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of
2025-12-11 21:04
Elicio Announces Additional Immunogenicity Data From Ongoing Phase 2 AMPLIFY-7P Trial Evaluating ELI-002 7P In Patients With mKRAS PDAC And New Preclinical Data On Immunotherapy Candidate ELI-004, For Treatment Of Solid Tumors
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002 7P induced
2025-11-07 22:10
Elicio Therapeutics Announced That Preliminary Analysis Of Patients In The Ongoing Phase 2 AMPLIFY-7P Trial Indicated That Specific Human Leukocyte Antigen Types; ELI-002 7P Shows Broad T-Cell Response Against mKRAS-Mutated Cancers Across Diverse Patient HLA Types
ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a
2025-10-27 20:22
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics announced preliminary results from its Phase 2 AMPLIFY-7P trial showing ELI-002 7P induced robust mKRAS-specific T cell responses across a diverse HLA population. Among 89 patients, 1,132 unique HLA types were identified, with 99% of patients (88/89) developing mKRAS-specific T cell responses. These findings suggest ELI-002 7P may benefit a broad spectrum of pancreatic ductal adenocarcinoma (PDAC) patients, addressing a critic...
2025-10-27 12:00
